echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Treat early breast cancer!

    Treat early breast cancer!

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TextPharmaceutical Guanlan

    On January 6, Eli Lilly and Company announced that its new anti-tumor drug Abeccil (trade name: Weizhe) was approved by China's National Medical Products Administration (NMPA) in combination with tamoxifen or aromatized Endocrine therapy such as enzyme inhibitors is suitable for adjuvant therapy in adult patients with HR-positive, HER2-negative, lymph node-positive, high recurrence risk and Ki-67≥20% early breast cancer
    .
    According to a press release, abeccil has thus become the first and only CDK4/6 inhibitor approved for patients with early breast cancer in mainland China


    .


    Breast cancer is the most common cancer in women worldwide
    .
    It is estimated that 90% of breast cancers are diagnosed at an early stage


    .


    Abeccil is an inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, activated by binding to cyclin
    D.
    It inhibits the phosphorylation of Rb and blocks the progression of cells from the G1 phase to the S phase of the cell cycle, resulting in cellular senescence and apoptosis


    .


    According to the press release, the approval of the new indication is based on the results of a randomized multicenter Phase 3 clinical study called monarchE
    .
    The data show that in adult patients with HR-positive, HER2-negative, node-positive, high-risk of early breast cancer, and Ki-67 ≥ 20%, compared with standard endocrine therapy, abeccil combined with standard endocrine therapy significantly reduces high-risk early breast cancer.


    The recurrence risk of cancer patients was 37%, and the 3-year invasive disease-free survival (IDFS) rate was 7.


    References:

    [1] Eli Lilly’s new breast cancer drug Weize® (Abecili Tablets) added early breast cancer indications, creating a new era of adjuvant therapy for HR+, HER2- early breast cancer patients at high risk.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.